Blog
- FDA 2025 Approvals: Innovation and Next-Gen Blockbuster Drugs
- 2026 FDA Drug Approvals: Blockbusters to Watch
- FDA Approved PEGylated Drugs By 2026
- FDA Approved Antibody-Drug Conjugates (ADCs) By 2026
- The Rise of PD-L1 ADCs: A New Paradigm in Cancer Therapy
- FGF21 agonist for MASH: Current Status
- In Vivo CAR-T Delivery: mRNA-LNP System
- Next-Generation mRNA-LNPs: Strategies to Reduce Anti-PEG Antibody Responses
- CD388, a Novel Drug Fc-Conjugate (DFC) to Prevent Influenza Infection
- 21 Antibody-drug Conjugates (ADCs) Approved by FDA/EMA/NMPA/PMDA